Daré Bioscience

Focus: Daré Bioscience is a women's health-focused biotech company headquartered in San Diego, specializing in therapies for underserved gynecological and reproductive health conditions. The company operates as a pre-revenue biotech with a diversified pipeline spanning bacterial vaginosis, sexual dysfunction, contraception, and obstetric indications.

Women's Health

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Daré Bioscience

AI assessmentNot Hiring

No open roles listed right now. Follow Daré Bioscience to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Ovaprene

Contraception

N/A

Ovaprene

Contraception

N/A

Progesterone

Pre Term Birth

Help build intelligence for Daré Bioscience

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Mission-driven focus on women's health, a historically under-resourced therapeutic area with significant unmet medical needs and limited competition
Diversified pipeline of 11 active programs spanning multiple indications, reducing single-asset concentration risk and offering exposure across development stages (Phase 1 through Phase 3)
San Diego location provides access to a mature biotech ecosystem with strong networking and mobility to neighboring companies

Watch Out For

Pre-revenue status with no marketed products creates significant cash-burn risk and uncertainty around funding runway and long-term viability
Heavily early-stage pipeline with only 1 Phase 3 program and 7 Phase 1 studies suggests 5+ years to first potential approval, delaying revenue inflection and investor confidence

Generated by Claude from Daré Bioscience's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Sildenafil

Sexual Arousal Disorder

Phase 1

Clinical Trials (1)

NCT05765487Using Thermography to Assess the Affects of Sildenafil Cream, 3.6%

Phase 1

IVR Dose 1

Vulvovaginal Atrophy

Phase 1

Clinical Trials (1)

NCT05418426A Phase 1, Open-Label, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of DARE-HRT1 in Healthy PostMenopausal Women

Phase 1

Diclofenac 1%

Dysmenorrhea Primary

Phase 1

Clinical Trials (1)

NCT05752526A Study of Diclofenac Gel in Women With Primary Dysmenorrhea

Phase 1

DARE-BV1

Bacterial Vaginosis

Phase 1

Clinical Trials (1)

NCT05354050Pharmacokinetic Study of DARE-BV1

Phase 1

Tamoxifen

Vulvar Atrophy

Phase 1/2

Clinical Trials (1)

NCT05378269Study of Intravaginal Tamoxifen in PostMenopausal Women With VVA

Phase 1/2

IVR Dose 1

Vulvovaginal Atrophy

Phase 1/2

Clinical Trials (1)

NCT05367973Study of DARE-HRT1 Over 12 Weeks in Healthy PostMenopausal Women

Phase 1/2

Sildenafil

Female Sexual Arousal Disorder

Phase 2

Clinical Trials (1)

NCT04948151Multi-Center Study to Evaluate the Efficacy and Safety of Sildenafil Cream (3.6%) in Premenopausal Patients With Female Sexual Arousal Disorder

Phase 2

DARE-BV1clindamycin phosphate vaginal gel, 2%

Bacterial Vaginosis

Phase 3

Clinical Trials (1)

NCT04370548DARE-BV1 in the Treatment of Bacterial Vaginosis (DARE-BVFREE)

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 8 clinical trials

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo